bioAffinity Technologies, Inc. (BIAF)

bioAffinity Technologies will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)n/a
Net Income (ttm)-6.33M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About BIAF

bioAffinity Technologies, Inc. is addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Our Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Research and optimization of our platform technologies are conducted in our laboratories at The University of Texas at San Antonio. We are developing our platform technologies so that, in the fu...

IndustryHealth Care
Founded2014
CEOMaria Zannes
Employees11
Stock ExchangeNASDAQ
Ticker SymbolBIAF
Full Company Profile

Financial Performance

Financial Statements

News

Lung cancer diagnostics developer bioAffinity Technologies files for a $15 million IPO

bioAffinity Technologies, which is developing a noninvasive test for early detection of lung cancer, filed on Monday with the SEC to raise up to $15 million in an initial public offering.

3 weeks ago - Renaissance Capital

bioAffinity Technologies IPO Registration Document (S-1)

bioAffinity Technologies has filed to go public with an IPO on the NASDAQ.

3 weeks ago - SEC